Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PLAU encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. Additionally we are shipping PLAU Antibodies (334) and PLAU Kits (88) and many more products for this protein.
Showing 10 out of 58 products:
Human PLAU Protein expressed in Human - ABIN491612
Reichel, Uhl, Lerchenberger, Puhr-Westerheide, Rehberg, Liebl, Khandoga, Schmalix, Zahler, Deindl, Lorenzl, Declerck, Kanse, Krombach: Urokinase-type plasminogen activator promotes paracellular transmigration of neutrophils via mac-1, but independently of urokinase-type plasminogen activator receptor. in Circulation 2011
Show all 6 references for ABIN491612
Human PLAU Protein expressed in Human Cells - ABIN2003435
Nagai, Hiramatsu, Kanéda, Hayasuke, Arimura, Nishida, Suyama: Molecular cloning of cDNA coding for human preprourokinase. in Gene 1985
Show all 4 references for ABIN2003435
Human PLAU Protein expressed in Human - ABIN491028
Komissarov, Florova, Idell: Effects of extracellular DNA on plasminogen activation and fibrinolysis. in The Journal of biological chemistry 2011
Mouse (Murine) PLAU Protein expressed in Insect Cells - ABIN2544534
Bryer, Fantuzzi, Van Rooijen, Koh: Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. in Journal of immunology (Baltimore, Md. : 1950) 2008
ApaL1 and Taq1 single nucleotide polymorphisms of the urokinase and VDR (show CYP27B1 Proteins) genes are associated with recurrent urolithiasis in a Caucasian population.
1,25D3 works as a modifier of NF-kappaB (show NFKB1 Proteins)/GPX1 (show GPX1 Proteins)/uPA (show PRAP1 Proteins) expression, inhibiting cisplatin-resistance and cell invasive ability of salivary adenoid cystic carcinoma cells
Resveratrol inhibited hypoxia-induced HIF-1alpha (show HIF1A Proteins) protein expression. Resveratrol also suppressed hypoxiainduced expression of metastatic-related factors, uPA (show PRAP1 Proteins) and MMP2 (show MMP2 Proteins).
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
These findings strongly support the use of uPA (show PRAP1 Proteins)/PAI-1 (show SERPINE1 Proteins) together with clinic-pathological parameters as an evidence-based, clinically relevant and inexpensive decision tool in the routine of a breast center.
Data suggest that enhanced levels of uPA (show PRAP1 Proteins) in breast cancer modulate the mitogenic effects of EGF (show EGF Proteins) which helps to better understand breast cancer pathogenesis.
Results found high levels of uPA (show PRAP1 Proteins) and uPAR (show PLAUR Proteins) exclusively in metastatic osteosarcoma (OS)cells and suggest that malignant conversion of OS cells to uPA (show PRAP1 Proteins)/uPAR (show PLAUR Proteins) axis in an autocrine and paracrine fashion.
The morphologically normal tissue adjacent to the tumor shows the substantial expression of MMP-2 (show MMP2 Proteins) and MMP-9 (show MMP9 Proteins) and in some cases the enhanced activity of uPA (show PRAP1 Proteins) and ACE (show ACE Proteins), which makes an additional contribution to the increased invasive potential of tumor
Crystal structure of uPA (show PRAP1 Proteins) bound with cyclic peptidic inhibitors.
data on the stromal macrophages immunoreactivity of uPAR (show PLAUR Proteins), MMP-2 (show MMP2 Proteins), and MMP-9 (show MMP9 Proteins) in a few small cell lung cancer (SCLC) and lung squamous cell carcinoma (SCC (show CYP11A1 Proteins)) biopsies was included. uPAR (show PLAUR Proteins), MMP-2 (show MMP2 Proteins), and MMP-9 (show MMP9 Proteins) were confirmed in stromal cells including macrophages
GM-CSF (show CSF2 Proteins) and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.
Plau deficiency does not worsen controlled cortical impact-induced brain pathology or epileptogenesis caused by TBI (show TBPL1 Proteins).
we have firstly shown a fundamental mechanism of urokinase system(uPa and uPAR (show PLAUR Proteins))-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
Pharmacological inhibition of either uPA or selected MMPs decreased atherosclerosis in transgenic uPA mice.
Study shows that the competitive expression or activity of tPA (show PLAT Proteins) and/or PAI-1 (show SERPINE1 Proteins), rather than an altered uPA expression, determines the plasmin (show PLG Proteins)-mediated Abeta (show APP Proteins) proteolysis in brains affected by Alzheimer's disease
Porphyromonas gingivalis-derived RgpA-Kgp complex activates the macrophage uPA.
beta-elemene downregulates expression of uPA, uPAR (show PLAUR Proteins), MMP-2 (show MMP2 Proteins), and MMP-9 (show MMP9 Proteins) in a murine intraocular melanoma model
Data indicate that closed head trauma sequentially releases tissue-type plasminogen activator (tPA (show PLAT Proteins)) followed by delayed synthesis and release of urokinase plasminogen (show PLG Proteins) activator (uPA) from injured brain.
Binding of urokinase to urokinase plasminogen activator receptor (show PLAUR Proteins) promotes dendritic spine recovery and functional outcome after ischemic stroke.
uPA-mediated arterial constriction is a vasomotor process that is mediated by uPA catalytic activity, not by the NH(2)-terminal domains.
Data show that urokinase-type plasminogen activator (uPA) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA receptor (uPAR (show PLAUR Proteins)) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Proteins)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA/uPAR (show PLAUR Proteins) binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
These data indicated that E. coli LPS (show IRF6 Proteins) led to an increase in u-PA activity and RNA expression of u-PA and u-PAR (show PLAUR Proteins) in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
The plasminogen/plasminogen (show PLG Proteins) activator/plasmin (show PLG Proteins) system is activated during gamete interaction and regulates the sperm entry into the oocyte.
stage-dependent regulation of granulosa cell PA and SerpinE2 (show SERPINE2 Proteins) production, consistent with a role in extracellular matrix remodeling during follicle growth.
This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
urokinase-type plasminogen activator
, U-plasminogen activator
, plasminogen activator, urokinase
, plasminogen activator, urinary
, Urinary plasminogen activator, urokinase
, urokinase plasminogen activator preproprotein